Terapevt Arkh
-
At an international online expert meeting held on September 16, 2021, the results of the empagliflozin research program EMPA-REG Outcome, EMPEROR-Reduced and EMPEROR-Preserved were reviewed. We analyzed cardiovascular and renal outcomes during the treatment with empagliflozin in patients with chronic heart failure, regardless of the presence of type 2 diabetes mellitus. The positive results of the EMPEROR-Preserved study are updated and their significance for clinical practice is discussed. Several proposals have been adopted that will accelerate the introduction of empagliflozin therapy into practice in patients with heart failure and overcome clinical inertia.
-
To conduct comparative analysis of histological remission in patients with moderate and severe ulcerative colitis (UC), receiving biological therapy vedolizumab, mesenchymal stem cell (MSC) treatment and combined stem cells and vedolizumab therapy. ⋯ Our study showed that clinical and endoscopic remission in UC patients does not always correlate with histological remission. Combined anti-cytokine and stem cells therapy contributes to achieve deep remission and decrease mucosa inflammation rather than single MSC or vedolizumab treatment. Deep remission could be achieved by earlier start of biological therapy. FC could be a predictor and marker of mucosa healing and histological remission.
-
A Council of Experts was held in Moscow with the scientific and organizational support of the National Medical Research Center for Therapy and Preventive Medicine and the Russian Society for the Prevention of Noncommunicable Diseases. Leading experts in various fields of medicine discussed the possibility of using antiplatelet drugs as prevention of arterial vascular complications of COVID-19 in different time periods of the disease. The main outcome of the Council of Experts was a resolution reflecting the general view of the scientific community on the possibility of increasing the use of acetylsalicylic acid in patients with coronavirus infection.